Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia

The treatment of blast phase chronic myeloid leukemia (bpCML) remains a challenge bostik roll-cote due at least in part to drug resistance of leukemia stem cells (LSCs).Recent clinical evidence suggests that the BCL-2 inhibitor venetoclax in combination with ABL-targeting tyrosine kinase inhibitors (TKIs) can eradicate bpCML LSCs.In this report, we

read more